Skip to main content

Table 3 Factors associated with patients’ progression-free survival

From: Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma

Variables

Univariate analysis

Multivariate analysis

HR (95% CI)

P

aHR (95% CI)

P

aHR (95% CI)

P

aHR (95% CI)

P

aHR (95% CI)

P

FIGO stage

 III-IV (n = 290) vs. I-II (n = 48)

4.973 (2.631–9.399)

< 0.001

2.729 (1.397–5.331)

0.003

2.915 (1.494–5.687)

0.002

2.933 (1.504–5.720)

0.002

2.913 (1.494–5.677)

0.002

Neoadjuvant chemotherapy

 Yes (n = 113) vs. No (n = 225)

2.160 (1.639–2.845)

< 0.001

2.107 (1.572–2.823)

< 0.001

2.003 (1.497–2.680)

< 0.001

1.973 (1.471–2.646)

< 0.001

1.994 (1.489–2.671)

< 0.001

Operative time, h

  ≥5.0 (n = 161) vs. <5.0 (n = 177)

1.477 (1.125–1.938)

0.005

1.331 (1.003–1.767)

0.048

1.325 (0.998–1.759)

0.052

1.358 (1.023–1.802)

0.034

1.392 (1.048–1.849)

0.022

Residual tumor after surgery

 Residual (n = 85) vs. R0 (n = 253)

2.555 (1.897–3.442)

< 0.001

2.333 (1.719–3.168)

< 0.001

2.323 (1.713–3.150)

< 0.001

2.267 (1.671–3.076)

< 0.001

2.279 (1.681–3.091)

< 0.001

MAP under 65 mmHg, min

 Continuous (n = 338)

1.002 (0.999–1.005)

0.289

        

  ≥30.0 (n = 107) vs. <30.0 (n = 231)

1.423 (1.073–1.887)

0.014

1.376 (1.035–1.830)

0.028

      

MDPE (%)

 Continuous (n = 338)

0.993 (0.981–1.005)

0.244

        

  <−4.0 (n = 183) vs. ≥−4.0 (n = 155)

1.349 (1.025–1.775)

0.032

  

1.351 (1.024–1.783)

0.033

    

Wobble (%)

 Continuous (n = 338)

1.096 (1.032–1.165)

0.003

    

1.082 (1.018–1.150)

0.012

  

  ≥7.5 (n = 159) vs. <7.5 (n = 179)

1.449 (1.106–1.900)

0.007

      

1.445 (1.100–1.899)

0.008

  1. Abbreviations: aHR Adjusted hazard ratio, BMI Body mass index, CI Confidence interval, FIGO International Federation of Gynecology and Obstetrics, HR Hazard ratio, MAP Mean arterial blood pressure, MDPE Median performance error, R0 Complete cytoreduction